QIAGEN Appoints Mark Stevenson to Supervisory Board, Strengthening Governance and Operational Expertise
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA), a global leader in sample and assay technologies serving molecular diagnostics, life sciences research, and applied testing markets, has announced the appointment of Mark Stevenson as an independent member of its Supervisory Board, effective January 23, 2026. Stevenson will stand for election by shareholders at the company’s next Annual General Meeting, scheduled to take place in June 2026.
The appointment reflects QIAGEN’s continued focus on enhancing its governance structure with seasoned leaders who bring deep operational expertise and global industry perspective. Stevenson’s extensive background in scaling complex life sciences organizations and overseeing global operations is expected to further strengthen the Supervisory Board’s ability to support QIAGEN’s long-term strategy, capital allocation discipline, and operational excellence.
At the same time, QIAGEN announced that Prof. Dr. Ross Levine stepped down from the Supervisory Board on January 23, 2026, following his appointment to a new senior leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. While departing the Supervisory Board, Prof. Levine will continue to play a vital role at QIAGEN as Chair of the QIAGEN Scientific Advisory Board, ensuring continuity in scientific guidance and innovation leadership.
Strengthening Board Expertise for the Next Phase of Growth
QIAGEN’s Supervisory Board plays a central role in overseeing the company’s strategic direction, financial discipline, and governance practices. The addition of Mark Stevenson brings decades of experience in managing global life sciences platforms at scale, a capability that is increasingly important as QIAGEN continues to operate across diverse markets and geographies.
“We are pleased to welcome Mark Stevenson to our Supervisory Board,” said Stephen H. Rusckowski, Chairman of the Supervisory Board. “Mark brings deep operational leadership and global life sciences experience at scale. His background will further strengthen the Supervisory Board’s ability to provide effective oversight and support disciplined capital allocation.”
Rusckowski emphasized that Stevenson’s hands-on experience in senior operating roles across the life sciences industry will be particularly valuable as QIAGEN continues to balance investment in innovation with operational efficiency and shareholder value creation.
Stevenson’s appointment is aligned with QIAGEN’s broader governance philosophy of combining scientific excellence with strong operational and financial oversight. As the company continues to expand its portfolio across molecular diagnostics and life sciences applications, the Supervisory Board’s composition reflects a deliberate effort to bring together leaders with complementary skills.
A Thoughtful Transition Following a Decade of Service
The announcement also marks a transition on the Supervisory Board following the departure of Prof. Dr. Ross Levine, who has served as a board member for nearly a decade. During his tenure, Prof. Levine provided critical scientific and clinical insight that helped guide QIAGEN’s innovation agenda and long-term research priorities.
“I would also like to express our sincere appreciation to Ross Levine for his outstanding service on the Supervisory Board over the last decade,” Rusckowski said. “Ross is an esteemed physician-scientist whose scientific leadership and clinical perspectives have made a lasting contribution to QIAGEN.”
Prof. Levine’s decision to step down from the Supervisory Board follows his appointment as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center, one of the world’s leading institutions for cancer research and clinical care. His new role reflects the growing demands and responsibilities associated with leading scientific strategy at a major academic medical center.
Despite stepping down from the Supervisory Board, Prof. Levine will continue to serve as Chair of the QIAGEN Scientific Advisory Board, where he will remain closely involved in shaping the company’s research priorities and innovation roadmap.
“We wish him every success in his new leadership role and are grateful that he will continue to lead our Scientific Advisory Board, where his guidance remains critical to our innovation agenda,” Rusckowski added.
This continued engagement ensures that QIAGEN retains access to Prof. Levine’s scientific expertise and clinical perspective, reinforcing the company’s commitment to evidence-based innovation and translational science.
Mark Stevenson: A Proven Leader in Global Life Sciences Operations
Mark Stevenson brings more than 30 years of experience in the life sciences and technology sectors, with a career defined by operational leadership, organizational scale, and execution excellence. His background spans some of the most influential companies in the global life sciences ecosystem, where he held senior executive roles during periods of significant growth and transformation.
Most recently, Stevenson served as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, one of the world’s largest providers of scientific instruments, diagnostics, and laboratory services. In that role, he was responsible for overseeing global operations across a highly diversified portfolio, managing complex supply chains, and driving operational performance across multiple business units and regions.
During his tenure at Thermo Fisher Scientific, Stevenson played a key role in supporting the company’s growth strategy, which included integrating acquisitions, expanding manufacturing capabilities, and ensuring consistent execution across a global footprint. His experience navigating large-scale organizations with significant regulatory, operational, and logistical complexity is directly relevant to QIAGEN’s global operations.
Earlier in his career, Stevenson held senior leadership positions at Life Technologies and Applied Biosystems, two companies that played pivotal roles in shaping the modern life sciences tools market. At both organizations, he served as President and Chief Operating Officer, overseeing business operations, commercial strategy, and organizational development.
These roles provided Stevenson with firsthand experience in managing product portfolios that spanned research, diagnostics, and applied markets—an experience that closely aligns with QIAGEN’s diversified business model. His leadership during periods of technological advancement and market expansion further underscores his ability to guide organizations through change while maintaining operational discipline.
In addition to his executive leadership experience, Stevenson currently serves as an Operating Partner at Fivespan Partners, a private equity firm focused on investing in growth-oriented companies. In this capacity, he advises portfolio companies on strategy, operations, and value creation, bringing an investor’s perspective to governance and oversight.
He also serves on the board of directors of Ingersoll Rand, a publicly listed industrial company in the United States, further demonstrating his experience in corporate governance and public company oversight.
QIAGEN operates at the intersection of life sciences research and molecular diagnostics, providing solutions that enable advances in healthcare, academic research, and applied testing. As the company continues to evolve its portfolio and respond to changing market dynamics, strong governance and operational insight remain critical components of its success.
Stevenson’s appointment is expected to support QIAGEN’s efforts to maintain disciplined capital allocation, optimize operational performance, and execute on strategic priorities across its global footprint. His experience working with complex, multinational organizations positions him well to contribute to board-level discussions on efficiency, scalability, and long-term value creation.
At the same time, the continued involvement of Prof. Levine as Chair of the Scientific Advisory Board ensures that QIAGEN’s innovation strategy remains grounded in cutting-edge science and clinical relevance. Together, these leadership developments underscore QIAGEN’s balanced approach to governance—combining scientific excellence with operational rigor.
With the appointment of Mark Stevenson and the continued engagement of Ross Levine in a scientific advisory capacity, QIAGEN enters the next phase of its governance evolution with a strengthened leadership structure. The company remains focused on delivering innovative solutions that address unmet needs in diagnostics and life sciences, while maintaining the operational discipline and oversight required to succeed in a complex global environment.
As QIAGEN prepares for its Annual General Meeting in June 2026, shareholders will have the opportunity to formally elect Stevenson to the Supervisory Board, further reinforcing the company’s commitment to transparent governance and long-term strategic execution.
Source link: https://www.businesswire.com
